The Lack and Cytomegalovirus-Specific Cellular Immune Response May Contribute to the Onset of Organ Infection and Disease in Lung Transplant Recipients

Abstract

Cellular immune response has been demonstrated to play a role in the control of human cytomegalovirus (HCMV) replication in organ transplant recipients. Herein, HCMV-specific T-cell response and association to the onset of organ infection/disease were prospectively evaluated by EliSPOT assay in a population of 46 lung transplant (LT) recipients at 1, 3, 6, 9 and 12 months post-transplantation. According to our centre's practice, a combined prolonged antiviral prophylaxis (HCMV-IG for 12 months and ganciclovir or valganciclovir for 3 weeks from postoperative day 21) was given to all LT recipients. HCMV-DNA was concomitantly detected on bronchoalveolar lavage (BAL) and whole blood by real-time PCR. Approximately one third of patients resulted HCMV persistently non-responder; the rate of HCMV infection, as evaluated by HCMV-DNA positivity, tended to be higher in non-responders. Mean viral load on BAL was significantly higher in non-responders vs other patients (p <0.001). Temporal profile of infections appeared related to the HCMV responder status with a shorter time to onset of infection post-transplantation and a longer duration in non-responders. The occurrence of organ disease (i.e. pneumonia) tended to be higher in non-responders, with poor prognosis, as death occurred in one of three non-responder patients that developed HCMV pneumonia. The lack of HCMV-specific cellular response can contribute to the onset of organ infection and disease also in patients in which antiviral prophylaxis was adopted; this could be due to the potential occurrence of incomplete control of replication in lungs or a delayed priming of T-cell reconstitution.

Keywords

human cytomegalovirus cellular immune response lung transplantation

References

Snydman

Limaye

Potena

Zamora

. Update and review: State-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011; 43(S):1–17.

Rhada

Jordan

Puliyanda

Bunnapradist

Petrosyan

Amet

Toyoda

. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 2005; 5:110–7.

Shlobin

West

Lechtzin

Miller

Borja

Orens

Dropulic

McDyer

. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 2006; 176:2625–34.

Chiereghin

Gabrielli

Zanfi

. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. Transplant Proc 2010; 42:69–73.

Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar, transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779–95.

Zhang

Caspell

Karulin

. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring – even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol 2009; 6:227–34.

Costa

Astegiano

Terlizzi

. Evaluation and significance of cytonegalovirus-specific cellular immune response in lung transplant recipients. Transplant Proc 2011; 43:1159–61.

Costa

Delsedime

Solidoro

. Herpesviruses detection by quantitative real-time polymerase chain reaction in bronchoalveolar lavage and transbronchial biopsy in lung transplant: Viral infections and histopathological correlation. Transplant Proc 2010; 42:1270–4.

Gerna

Lilleri

Furione

Baldanti

. Management of human cytomegalovirus infection in transplantation: Validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection New Microbiol 2011; 34:229–54.

10.

Christie

Edwards

Aurora

. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant 2008; 27:957–69.

11.

Gerna

Lilleri

Rognoni

. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009; 9:1142–50.

12.

Sester

Gärtner

Wilkens

. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5:1483–9.

13.

Egli

Köhli

Dickenmann

Hirsch

. Inhibition of polyomavirus-specific T-cell responses by immunosuppressive drugs. Transplantation 2009; 88:1161–8.

14.

Hodge

Mukaro

Reynolds

Hodge

. Role of increased CD8/CD28(null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease. Clin Exp Immunol 2011; 166:94–102.

15.

Domagala-Kulawik

Hoser

Dabrowska

Safianowska

Chazan

. CD4+/CD25+ cells in systemic inflammation in COPD. Scan J Immunol 2011;73:59–65.